BeyondSpring (BYSI) Other Non-Current Assets (2016 - 2026)
BeyondSpring (BYSI) posted Other Non-Current Assets of $5.3 million for Q1 2026, down 34.15% sequentially from $8.0 million in Q4 2025, and down 76.65% YoY from $22.6 million in Q1 2025.
BeyondSpring (BYSI) Other Non-Current Assets (2016 - 2026) Analysis & Trends
BeyondSpring has reported Other Non-Current Assets for 11 years, with the latest figure at $5.3 million in Q1 2026.
- Quarterly Other Non-Current Assets fell 76.65% year-over-year to $5.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.3 million (down 76.65% YoY) and the FY2025 annual result came in at $8.0 million, down 68.35% from the prior year.
- Other Non-Current Assets retreated to $5.3 million in Q1 2026 per BYSI's latest filing, from $8.0 million in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $25.3 million in Q4 2024 and troughed at $114000.0 in Q2 2022.
- A 5-year average of $8.6 million and a median of $5.3 million in 2026 frame the typical range for Other Non-Current Assets.
- The sharpest annual moves came in 2022 and 2025: Other Non-Current Assets slumped 91.83% in 2022, then soared 3462.81% in 2025.
- Over 5 years, Other Non-Current Assets stood at $347000.0 in 2022, then jumped by 1404.03% to $5.2 million in 2023, then surged by 385.67% to $25.3 million in 2024, then tumbled by 68.35% to $8.0 million in 2025, then sank by 34.15% to $5.3 million in 2026.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $5.3 million, $8.0 million, and $11.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 65.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 104.44 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 62.96 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 202.31 Mn |
| 10 | BeyondSpring | 30.22 Mn | 30.22 Mn | - | 4.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.27 Mn |
| Mar 31, 2026 | 5.28 Mn |
| Dec 31, 2025 | 8.02 Mn |
| Sep 30, 2025 | 11.41 Mn |
| Jun 30, 2025 | 15.71 Mn |
| Mar 31, 2025 | 22.63 Mn |
| Dec 31, 2024 | 25.35 Mn |
| Jun 30, 2024 | 441,000.00 |
| Dec 31, 2023 | 5.22 Mn |
| Jun 30, 2023 | 341,000.00 |
| Dec 31, 2022 | 347,000.00 |
| Jun 30, 2022 | 114,000.00 |
| Dec 31, 2021 | 3.12 Mn |
| Sep 30, 2021 | 1.37 Mn |
| Jun 30, 2021 | 1.40 Mn |
| Mar 31, 2021 | 1.30 Mn |
| Dec 31, 2020 | 1.28 Mn |
| Sep 30, 2020 | 1.18 Mn |
| Jun 30, 2020 | 1.09 Mn |
| Mar 31, 2020 | 941,000.00 |